Evidence map›Paper›PMID 26518487›Full record

Observational studyBMC infectious diseases2015

Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients.

Guillermo Cuervo, Mariana Camoez, Evelyn Shaw, María Ángeles Dominguez, Oriol Gasch, Belén Padilla, Vicente Pintado, Benito Almirante, José Molina, Francisco López-Medrano and 11 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Guillermo CuervoDepartment of Infectious Diseases, Hospital Universitari de Bellvitge; Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. guillermocuervo@hotmail.com.
Mariana CamoezDepartment of Microbiology, H. Bellvitge, Barcelona, Spain. mcamoez@bellvitgehospital.cat.
Evelyn ShawDepartment of Infectious Diseases, Hospital Universitari de Bellvitge; Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. evelyn.shaw@bellvitgehospital.cat.
María Ángeles DominguezDepartment of Microbiology, H. Bellvitge, Barcelona, Spain. adominguez@bellvitgehospital.cat.
Oriol GaschDepartment of Infectious Diseases, H. Parc Taulí, Sabadell, Spain. oriol.gasch@gmail.com.
Belén PadillaDepartment of Infectious Diseases, H. Gregorio Marañón, Madrid, Spain. belenpadilla@telefonica.net.
Vicente PintadoDepartment of Infectious Diseases, H. Ramón y Cajal, Madrid, Spain. vicente.pintado@salud.madrid.org.
Benito AlmiranteDepartment of Infectious Diseases, H. Vall d'Hebrón, Barcelona, Spain. balmirante@vhebron.net.
José MolinaDepartment of Infectious Diseases, H. Virgen del Rocío, Sevilla, Spain. josemolinagb@gmail.com.
Francisco López-MedranoDepartment of Infectious Diseases, H. 12 de Octubre, Madrid, Spain. flmedrano@yahoo.es.
Enrique Ruiz de GopeguiDepartment of Microbiology, H. Son Espases, Palma de Mallorca, Spain. enrique.ruiz@ssib.es.
José A MartinezDepartment of Infectious Diseases, H. Clìnic, Barcelona, Spain. jamarti@clinic.ub.es.
Elena BereciartuaDepartment of Infectious Diseases, H. Cruces, Bilbao, Spain. elena.bereciartuabastarrica@osakidetza.net.
Fernando Rodriguez-LopezDepartment of Infectious Diseases, H. Reina Sofía, Córdoba, Spain. ernando.rodriguez.lopez.sspa@juntadeandalucia.es.
Carlos Fernandez-MazarrasaDepartment of Microbiology, H. Marqués de Valdecilla, Santander, Spain. u5596@humv.es.
Miguel Ángel GoenagaDepartment of Infectious Diseases, H. Donostia, Donostia, Spain. miguelangel.goenagasanchez@osakidetza.net.
Natividad BenitoDepartment of Infectious Diseases, H. de la Santa Creu i Sant Pau, Barcelona, Spain. nbenito@santpau.es.
Jesús Rodriguez-BañoDepartment of Infectious Diseases, H. Virgen de Macarena, Sevilla, Spain. jesusrb@us.es.
Elena EspejoDepartment of Infectious Diseases, H. Terrassa, Terrassa, Spain. eespejo@cst.cat.
Miquel PujolDepartment of Infectious Diseases, Hospital Universitari de Bellvitge; Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. mpujol@bellvitgehospital.cat.
REIPI/GEIH Study Group
Bellvitge University Hospital · ESHospital Clínic de Barcelona · ESHospital de Sant Pau · ESHospital General Universitario Gregorio Marañón · ESMarqués de Valdecilla University Hospital · ESResearch Institute Hospital 12 de Octubre · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Reina Sofía · ESHospital Universitario Virgen Macarena · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the study was to determine clinical and microbiological differences between patients with methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia (CRB) undergoing or not undergoing haemodialysis, and to compare outcomes.

methodsProspective multicentre study conducted at 21 Spanish hospitals of patients with MRSA bacteraemia diagnosed between June 2008 and December 2009. Patients with MRSA-CRB were selected. Data of patients on haemodialysis (HD-CRB) and those not on haemodialysis (non-HD-CRB) were compared.

resultsAmong 579 episodes of MRSA bacteraemia, 218 (37.7%) were CRB. Thirty-four (15.6%) were HD-CRB and 184 (84.4%) non-HD-CRB. All HD-CRB patients acquired the infection at dialysis centres, while in 85.3% of the non-HD-CRB group the infection was nosocomial (p < .001). There were no differences in age, gender or severity of bacteraemia (Pitt score); comorbidities (Charlson score ≥ 4) were higher in the HD-CRB group than in the non-HD-CRB group (73.5% vs. 46.2%, p = .003). Although there were no differences in VAN-MIC ≥ 1.5 mg/L according to microdilution, using the E-test a higher rate of VAN-MIC ≥ 1.5 mg/L was observed in HD-CRB than in non-HD-CRB patients (63.3% vs. 44.1%, p = .051). Vancomycin was more frequently administered in the HD-CRB group than in the non-HD-CRB group (82.3% vs. 42.4%, p = <.001) and therefore the appropriate empirical therapy was significantly higher in HD-CRB group (91.2% vs. 73.9%, p = .029). There were no differences with regard to catheter removal (79.4% vs. 84.2%, p = .555, respectively). No significant differences in mortality rate were observed between both groups (Overall mortality: 11.8% vs. 27.2%, p = .081, respectively), but there was a trend towards a higher recurrence rate in HD-CRB group (8.8% vs. 2.2%, p = .076).

conclusionsIn our multicentre study, ambulatory patients in chronic haemodialysis represented a significant proportion of cases of MRSA catheter-related bacteraemia. Although haemodialysis patients with MRSA catheter-related bacteraemia had significantly more comorbidities and higher proportion of strains with reduced vancomycin susceptibility than non-haemodialysis patients, overall mortality between both groups was similar.

Indexed as

Renal DialysisAgedAnti-Bacterial AgentsBacteremiaCatheter-Related InfectionsComorbidityCross InfectionFemaleHumansMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedProspective StudiesSpainStaphylococcal InfectionsTreatment OutcomeAnti-Bacterial AgentsVancomycin

Identifiers

PMID26518487
PMCPMC4628295
OpenAlexW2107231911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.